miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in or...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomed Res Int
Main Authors: Merhautova, Jana, Hezova, Renata, Poprach, Alexandr, Kovarikova, Alena, Radova, Lenka, Svoboda, Marek, Vyzula, Rostislav, Demlova, Regina, Slaby, Ondrej
Format: Artigo
Jezik:Inglês
Izdano: Hindawi Publishing Corporation 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433647/
https://ncbi.nlm.nih.gov/pubmed/26064968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/941980
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki